CDK1 and prostate cancer: In prostate cancer cells (PC-3 and DU-145), oridonin increased the expression levels of p53, p21, caspase-3, -9, and poly (ADP-ribose) polymerase (PARP), while it decreased cyclin-dependent kinase 1 (CDK1) levels [30].